Viking Therapeutics and Bluejay Therapeutics highlight progress in obesity management and neurological disease treatment with key clinical milestones.
Viking Therapeutics and Bluejay Therapeutics highlight progress in obesity management and neurological disease treatment with key clinical milestones.
Merck’s global license deal for HRS-5346 and Tiziana’s intranasal foralumab Phase 2 trial signify strides in cardiovascular and …
Abbott receives FDA approval to begin Phase 3 trial of its Intravascular Lithotripsy system aimed at improving outcomes …
Positive safety and efficacy review by independent board positions MaaT013 as Europe’s potential first-approved microbiome-based drug for severe …
Japanese pharma giant Taiho invests up to $1.14 billion in Swiss innovation, expanding its portfolio in antibody-drug conjugates …
Promising clinical results highlight Gilead’s innovative approach to long-acting HIV treatment, aiming to improve patient adherence and outcomes.
Major pharma players unveil significant clinical trial progress and strategic collaborations targeting obesity and cardiovascular health.
Recent developments underscore innovation in rare diseases and artificial intelligence, reshaping treatment paradigms and accelerating drug development.
March 2025 is marked by significant deal-making, promising clinical trial results, and innovations across small molecules, biologics, and …
European regulatory reforms are accelerating approvals for novel rare disease treatments, attracting global investment and expanding patient access.
Already a subscriber? Log in